1 tor (lansoprazole or omeprazole) and bismuth subsalicylate.

2 g three times a day for 2 weeks; and bismuth subsalicylate, 262 mg four times a day for 2 weeks, foll

3 alyzed before and after ingestion of bismuth subsalicylate (524 mg four times a day) for 3-7 days.

4         In this study the ability of bismuth subsalicylate, a compound that binds H2S, to reduce H2S

5 ionship between the concentration of bismuth subsalicylate and H2S release.

6                                      Bismuth subsalicylate, and 5-amniosalicylates are therapeutic op

7 eces were incubated with and without bismuth subsalicylate, and gas production was measured.

8 dition of a proton pump inhibitor or bismuth subsalicylate does not increase cure rate.

9 multaneous iodinated intravenous and bismuth subsalicylate enteric contrast material at DE CT.

10        We theorized that integrating bismuth subsalicylate into a quadruple therapy regimen could enh

11                           Regimen 3, bismuth subsalicylate + metronidazole + tetracycline + an H2-rec

12 t in which iodinated intravenous and bismuth subsalicylate oral contrast media were administered.

13 icylate, a model for the metallodrug bismuth subsalicylate (Pepto-Bismol).

14           Treatment of subjects with bismuth subsalicylate produced a >95% reduction in fecal H2S rel

15 th omeprazole (regimen 3; n = 4), or bismuth subsalicylate (regimen 4; n = 6).

16                       The ability of bismuth subsalicylate to dramatically reduce H2S could provide a

17 d of vonoprazan (20 mg) twice daily, bismuth subsalicylate twice daily, metronidazole (400 mg) three